Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Re-challenge with Dabrafenib and Trametinib in BRAF-mutant Melanoma
NCT02296996Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Oct 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in melanoma, sponsored by UZ Brussel. Started Oct 2014; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02296996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296996.